The ameliorative effect of AST2017-01 in an ovalbumin-induced allergic rhinitis animal model.
Inflamm Res
; 68(5): 387-395, 2019 May.
Article
in En
| MEDLINE
| ID: mdl-30874868
ABSTRACT
OBJECTIVE:
AST2017-01 is developed to be used for treatment and prevention of allergic diseases and composed of processed-Cordyceps militaris and processed-Rumex crispus. But, effect of AST2017-01 remains unclear in an allergic rhinitis (AR). So, this study aimed to explore the effects of AST2017-01 in ovalbumin (OVA)-induced AR animal model.METHODS:
OVA-induced AR animals were orally administered AST2017-01 and chrysophanol, an active component of AST2017-01 for 10 days.RESULTS:
In mice with AR, AST2017-01 and chrysophanol markedly decreased number of rubs, IgE, histamine, thymic stromal lymphopoietin, tumor necrosis factor-α, interleukin (IL)-1ß, IL-4, IL-5, and IL-13 in serum or nasal mucosa tissues. Moreover, activities and protein levels of caspase-1 were markedly diminished by oral administration of AST2017-01 and chrysophanol. Declines of macrophage inflammatory protein-2, intercellular adhesion molecules-1, eosinophil, and mast cells were also noted in nasal mucosa tissues of AST2017-01 and chrysophanol groups.CONCLUSIONS:
Taken together, these findings indicate that AST2017-01 has an anti-allergic effect as a therapeutic agent or functional food for treating and preventing AR.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Anti-Allergic Agents
/
Cordyceps
/
Rumex
/
Rhinitis, Allergic
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Inflamm Res
Journal subject:
ALERGIA E IMUNOLOGIA
/
PATOLOGIA
Year:
2019
Type:
Article